Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Clinical trial NCT02411656 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02411656
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Edema Erythema Estrogen Receptor Negative HER2/Neu Negative Peau d'Orange Progesterone Receptor Negative Recurrent Inflammatory Breast Carcinoma Stage IV Inflammatory Breast Carcinoma Triple-Negative Breast Carcinoma

Start date: 2015-06-11
Primary completion: 2024-06-15
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.